Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance.
about
Treatment of liver metastases in patients with neuroendocrine tumors of gastroesophageal and pancreatic originGuidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumoursCurrent status and perspectives of targeted therapy in well-differentiated neuroendocrine tumorsManagement of patients with hepatic metastases from neuroendocrine tumorsSystematic review reveals lack of quality in reporting health-related quality of life in patients with gastroenteropancreatic neuroendocrine tumoursChallenges in the Diagnosis and Management of Well-Differentiated Neuroendocrine Tumors of the Lung (Typical and Atypical Carcinoid): Current Status and Future ConsiderationsDiagnosis and treatment of carcinoid tumors.Progress in the treatment of neuroendocrine tumors.Irinotecan plus cisplatin followed by octreotide long-acting release maintenance treatment in advanced gastroenteropancreatic neuroendocrine carcinoma: IPO-NEC study.Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives.The endocrine tumor summit 2008: appraising therapeutic approaches for acromegaly and carcinoid syndrome.Quality of life, resource utilisation and health economics assessment in advanced neuroendocrine tumours: a systematic review.Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting.Transplantation and surgical strategies in patients with neuroendocrine liver metastases: protocol of four systematic reviews.The use of octreotide to manage symptoms of bronchorrhea: a case report.Treatment of liver metastases in patients with neuroendocrine tumors: a comprehensive review.Update on the treatment of neuroendocrine tumors.Targeted therapy in advanced well-differentiated neuroendocrine tumors.Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors.Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)Regional Gastrointestinal Transit Times in Patients With Carcinoid Diarrhea: Assessment With the Novel 3D-Transit SystemThe expanding role of somatostatin analogs in the management of neuroendocrine tumors.Lanreotide in the management of small bowel angioectasias: seven-year data from a tertiary centre.Lanreotide Autogel in the Treatment of Persistent Diarrhea following a Total Colectomy.Upper gastrointestinal carcinoid tumors incidentally found by endoscopic examinations.Validation of the EORTC QLQ-GINET21 questionnaire for assessing quality of life of patients with gastrointestinal neuroendocrine tumoursEmerging therapies for the treatment of patients with advanced neuroendocrine tumors.From somatostatin to octreotide LAR: evolution of a somatostatin analogueUpdate on management of midgut neuroendocrine tumors.Accomplishments in 2008 in the management of gastrointestinal neuroendocrine tumors.Somatostatin analogs therapy in gastroenteropancreatic neuroendocrine tumors: current aspects and new perspectives.Refractory carcinoid syndrome: a review of treatment options.Pharmacokinetic evaluation of lanreotide.A review of systemic and liver-directed therapies for metastatic neuroendocrine tumors of the gastroenteropancreatic tract.Diagnosis and management of gastrointestinal complications in adult cancer patients: evidence-based guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).Evolving treatment strategies for management of carcinoid tumors.Therapeutic strategies for neuroendocrine liver metastases.The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors.AACE/ACE disease state clinical review: diagnosis and management of midgut carcinoidsSomatostatin analogues in functioning gastroenteropancreatic neuroendocrine tumours: literature review, clinical recommendations and schedules.
P2860
Q21296729-74AD8857-7FD4-40E8-9F4E-983AFA5919C7Q24685837-62F76DE0-3197-46DC-AC46-0FC8F1FFD24DQ26823873-8FBD3525-37E9-4A37-80BB-BC522685CCCDQ27008832-0948EC30-F9B8-425E-9864-9812BBBE2460Q28071978-F43B86B7-A5B5-4317-BC23-DA7385ACB9EEQ28084155-6FFB9DFA-CCA7-482B-BD30-8D6ABB15FBB5Q33196127-A726A452-95E6-4709-9586-9449E303627CQ33643643-9F5FC212-466B-4B7E-AFA4-8DF9B11E9D71Q33648996-575721DA-F117-465B-9342-8D9AE7C1B9BCQ33753449-8482964A-160D-4B3E-8CC1-421CD96712E1Q34031906-BF767B6B-F451-4662-8DF5-D51F9A3569CDQ34400151-620EF8F3-0D7D-447E-88FB-6721E97530F6Q34743520-EFA27FA0-91B1-433C-85C5-A41CC85B5452Q35074937-4A6892C6-C7D2-429F-94AF-56F96EB4E577Q35129518-7533EA5E-DC57-4222-8022-12FC53C06D9CQ35371197-57A842BC-8A69-4E55-9F12-1E0141F08586Q35576166-92BA0B60-2EF9-4A99-B4B0-777F99068AD5Q35584497-968183C5-51F6-4E8D-A38B-390D716BC9BBQ35738251-4D89B47E-BAB5-4E97-8F15-EB60192197F6Q35760798-0DEE51CF-63B6-41E6-A9B4-252AF4C2050AQ35834537-85EF594B-4FF6-40AD-B486-7A08F9EB18FFQ36347272-A4E4E10A-C318-4F7D-8171-5398D4AFB58BQ36372377-EFA1520B-3569-48D9-9098-3041E08CC96CQ36386610-2F04FF61-B2BD-4481-8B52-5A8D7A3ACB28Q36474518-E8A3C95B-47C6-46BC-9264-7F955BC7D712Q36594133-0A7432DB-E95C-49DA-BE09-206F88ED32E1Q36866607-6174E000-D889-43B7-8BC2-7621F7065669Q36919554-86E3BAD2-12B5-4A11-AB56-9C26ED37DABEQ37025143-584FB880-AA75-40BE-A4DB-4F23F13B88B0Q37468838-5C2CB956-C183-4920-B9D0-0FDF638905ABQ37564373-5D205D07-A549-44D6-81B8-1CD12FE70A18Q37632161-8DDC0F38-20C9-4213-9C85-2CDB4B38ED33Q37780553-C2D584E9-381A-47BC-8343-AC6BB3D598D0Q37859615-9A2A8332-FF15-46E0-B541-476F989D4C7CQ38080794-CC021643-D4BA-42DE-B30A-CFC42A266E1FQ38124702-65FF5259-738E-4C22-B5FD-66448CD18D30Q38255979-086E4DB2-2B84-4CB6-AC04-5C02FCC4AB95Q38441413-52572307-6711-46F9-8B75-E8CAE81E85DEQ38472683-D5238154-2541-4261-B8E0-AD8E93B32E1CQ38647297-777320FF-C64B-4917-8070-347D6EB29E3B
P2860
Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
Treatment of carcinoid syndrom ...... acceptability, and tolerance.
@en
Treatment of carcinoid syndrom ...... acceptability, and tolerance.
@nl
type
label
Treatment of carcinoid syndrom ...... acceptability, and tolerance.
@en
Treatment of carcinoid syndrom ...... acceptability, and tolerance.
@nl
prefLabel
Treatment of carcinoid syndrom ...... acceptability, and tolerance.
@en
Treatment of carcinoid syndrom ...... acceptability, and tolerance.
@nl
P2093
P2860
P1433
P1476
Treatment of carcinoid syndrom ...... acceptability, and tolerance.
@en
P2093
G Bommelaer
J Blumberg
J L Wemeau
P Ruszniewski
P2860
P304
P356
10.1002/(SICI)1097-0142(20000215)88:4<770::AID-CNCR6>3.0.CO;2-0
P407
P577
2000-02-01T00:00:00Z